From military tech to ICU wards: Detect-ION’s bold new vision for breath-based infection testing

Detect-ION, LLC has announced a new collaboration with the Infectious Diseases Division at Mayo Clinic Florida to co-develop a non-invasive breath-based diagnostic for Pseudomonas aeruginosa, a drug-resistant pathogen implicated in pneumonia. The project, funded by the Mayo Clinic Advanced Innovation Research program, seeks to replace invasive procedures like bronchoscopy with real-time, point-of-care testing.

Can breath-based diagnostics solve pneumonia’s treatment-overdiagnosis dilemma in hospital settings?

The joint project between Detect-ION and Mayo Clinic Florida marks a strategic attempt to modernize how clinicians identify Pseudomonas aeruginosa, one of the most persistent and antibiotic-resistant pathogens driving hospital-acquired pneumonia and ventilator-associated infections. The bacterium is especially dangerous for immunocompromised patients, lung transplant recipients, and individuals with structural lung disease, where misdiagnosis or delayed treatment can quickly escalate into sepsis or respiratory failure.

Current diagnostic methods, including sputum and blood cultures or bronchoscopies, are either slow, invasive, or both. More critically, they often fail to distinguish between a colonized state and true infection, which drives the overuse of systemic antibiotics. That overuse, in turn, accelerates antimicrobial resistance and contributes to poor stewardship across hospitals.

By focusing on volatile organic compound (VOC) biomarkers in exhaled breath, this collaboration aims to shift that clinical paradigm. Detect-ION’s contribution lies in its CLARION platform, which integrates a miniaturized gas chromatograph and chip-scale mass spectrometer for rapid, lab-grade analysis of patient breath samples. When paired with Mayo Clinic’s expertise in infectious disease diagnostics, the result could be a platform capable of detecting pathogens like P. aeruginosa within minutes, without needing invasive intervention.

This project is initially focused on discovery-phase biomarker validation, but the ambition is clear: translate a dual-use defense-grade chemical detection platform into a frontline hospital tool with global scalability.

How does the CLARION platform attempt to redefine point-of-care diagnostics?

At the heart of the collaboration is CLARION, a diagnostic system originally developed through funding from U.S. government defense agencies including the Intelligence Advanced Research Projects Activity, the Defense Advanced Research Projects Agency, the Defense Threat Reduction Agency, and the Defense Innovation Unit. Detect-ION repurposed the platform’s high-resolution detection capabilities, originally designed for chemical threat sensing, for clinical use in respiratory infections.

The system’s key value proposition lies in portability and speed. Unlike conventional lab-based GC-MS tools that are bulky and require trained personnel, CLARION is built to be compact and user-friendly while delivering five-minute test results with high specificity. The platform analyzes trace VOC signatures exhaled from the lungs, enabling clinicians to identify pathogens, track disease severity, monitor treatment response, and potentially adjust therapies in real time.

This approach is particularly valuable in intensive care units, where patients are often intubated and vulnerable to invasive diagnostics or prolonged delays in diagnosis. If proven effective, CLARION could reduce reliance on empirical therapies, curb antimicrobial misuse, and enable more precise clinical decision-making.

What strategic role does Mayo Clinic play in advancing this diagnostic model?

While Detect-ION brings the technology, Mayo Clinic’s involvement is key to clinical validation, translational research, and downstream scalability. The project is being advanced under the Mayo Clinic Advanced Innovation Research (MC-AIR) initiative, which funds translational projects focused on disruptive healthcare technologies.

By embedding this development effort within Mayo Clinic Florida’s Infectious Diseases Division, the project gains access to patient cohorts, bioinformatics infrastructure, and a world-class clinical research environment. This positions the collaboration to accelerate from biomarker discovery to clinical testing faster than most early-stage diagnostic ventures.

Furthermore, the credibility conferred by Mayo Clinic’s institutional reputation may aid eventual regulatory review and hospital adoption. Should the breath test demonstrate meaningful sensitivity and specificity, Mayo Clinic could play a catalytic role in turning a research collaboration into a deployable commercial solution.

What makes Pseudomonas aeruginosa such a persistent diagnostic and treatment challenge?

P. aeruginosa is among the most challenging bacterial pathogens to detect and treat. It forms robust biofilms that shield it from immune detection and antibiotic penetration, and it has an uncanny ability to survive in hospital environments and medical devices. In patients with chronic lung disease or those undergoing mechanical ventilation, colonization is common—but not always clinically meaningful.

Distinguishing between benign colonization and invasive infection remains the core diagnostic hurdle. Traditional microbiology approaches cannot always resolve this distinction, which results in broad-spectrum antibiotic use by default. This feeds into a broader issue of antibiotic stewardship and resistance—a top global health concern.

A diagnostic platform that reliably correlates VOC biomarkers to infection severity or progression could directly address this challenge by enabling faster and more informed triage. The current market lacks such a solution that is non-invasive, real-time, and point-of-care ready.

Where does this technology fit within the broader diagnostics and infectious disease landscape?

Breath-based diagnostics are a growing field of interest across infectious disease, oncology, and even metabolic health. Several early-stage startups and research centers are exploring VOC-based detection for diseases like tuberculosis, malaria, and even cancer. Detect-ION’s CLARION system joins this trend but differentiates itself with its dual-use heritage and precision-grade hardware.

From a capital allocation and market entry perspective, positioning CLARION as a diagnostic tool for Pseudomonas aeruginosa is a high-stakes entry point. The unmet need is significant, the addressable patient base spans global ICUs, and the cost of delayed diagnosis remains high in both clinical and financial terms. If successful, CLARION could extend to other respiratory pathogens or bio-threat agents.

In strategic terms, Detect-ION’s approach reflects a broader trend in health technology—one that blends security-grade engineering with clinical utility to close long-standing diagnostic gaps. This is particularly compelling at a time when health systems are under pressure to reduce diagnostic latency, improve antibiotic targeting, and minimize unnecessary interventions.

What are the risks to adoption and scale if the project succeeds clinically?

Even if the collaborative project delivers strong proof-of-concept results, Detect-ION and Mayo Clinic face multiple execution risks. First is regulatory: the U.S. Food and Drug Administration approval process for novel diagnostics involving VOC biomarkers and new testing modalities is complex and may require multi-center clinical trials.

Second is reimbursement. For widespread adoption, the breath test must not only outperform bronchoscopy and culture-based methods in speed and accuracy but must also demonstrate cost-effectiveness. Payers and hospital systems will demand evidence that CLARION reduces downstream spending, improves outcomes, or meaningfully accelerates care pathways.

Third is manufacturing scale. Detect-ION will need to evolve from a defense contractor to a clinical manufacturing entity capable of producing devices that meet medical-grade quality assurance, sanitation, and supply chain reliability.

Finally, the company must position itself strategically against both established diagnostics players and newer entrants racing toward VOC-based breath analysis platforms in infectious disease and oncology. Mayo Clinic’s backing may help initially, but commercial traction will depend on health system integration, pricing, and trust in real-world performance.

Key takeaways on what this breath diagnostics project means for Detect-ION, Mayo Clinic, and the diagnostics industry

• Detect-ION and Mayo Clinic Florida have launched a co-development project to create a non-invasive breath test for detecting Pseudomonas aeruginosa, targeting ICU and lung transplant populations.

• The project leverages Detect-ION’s CLARION platform, a miniaturized GC-MS system originally built for chemical threat detection in defense, now adapted for clinical breath analysis.

• The collaboration aims to address diagnostic shortcomings in distinguishing between colonization and infection in hospital-acquired pneumonia, a key driver of antibiotic misuse.

• Mayo Clinic’s involvement offers translational infrastructure, credibility, and patient access, accelerating clinical readiness.

• VOC biomarkers could enable real-time, point-of-care pathogen detection with potential applications across infectious diseases, from tuberculosis to COVID-like pathogens.

• Execution risks include regulatory approvals, reimbursement hurdles, manufacturing scale-up, and competition from emerging VOC diagnostic players.

• If successful, the technology could contribute to global antibiotic stewardship by enabling earlier, targeted intervention and avoiding invasive procedures.

• The project reflects a broader convergence of military-grade sensing technologies with clinical diagnostics, offering a blueprint for dual-use tech spinouts in healthcare.